Alphabet Inc. - AUTOLUS THERAPEUTICS PLC ownership

AUTOLUS THERAPEUTICS PLC's ticker is AUTL and the CUSIP is 05280R100. A total of 52 filers reported holding AUTOLUS THERAPEUTICS PLC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Alphabet Inc. ownership history of AUTOLUS THERAPEUTICS PLC
ValueSharesWeighting
Q3 2023$1,626,950
-2.1%
698,2620.0%0.10%
+16.9%
Q2 2023$1,661,863
+29.3%
698,2620.0%0.09%
+25.4%
Q1 2023$1,284,802
-3.2%
698,2620.0%0.07%
-7.8%
Q4 2022$1,326,698
-11.2%
698,2620.0%0.08%
+1.3%
Q3 2022$1,494,000
-24.4%
698,2620.0%0.08%
-29.0%
Q2 2022$1,976,000
-32.1%
698,2620.0%0.11%
+13.8%
Q1 2022$2,912,000
-19.6%
698,2620.0%0.09%
+6.8%
Q4 2021$3,624,000
-20.8%
698,2620.0%0.09%
-19.3%
Q3 2021$4,574,000
-1.3%
698,2620.0%0.11%
+16.0%
Q2 2021$4,636,000
+15.9%
698,2620.0%0.09%
-41.6%
Q1 2021$4,001,000
-35.9%
698,2620.0%0.16%
-46.2%
Q4 2020$6,242,000
-23.2%
698,2620.0%0.30%
-21.7%
Q3 2020$8,128,000
-27.4%
698,2620.0%0.38%
-26.1%
Q2 2020$11,193,000
+167.2%
698,262
-0.2%
0.52%
+88.0%
Q1 2020$4,189,000
-54.6%
699,3520.0%0.28%
-50.7%
Q4 2019$9,231,000
+6.3%
699,3520.0%0.56%
+113.8%
Q3 2019$8,686,000
-22.9%
699,3520.0%0.26%
+22.0%
Q2 2019$11,260,000
-49.9%
699,352
-2.1%
0.21%
-81.6%
Q1 2019$22,472,000
-4.2%
714,0720.0%1.16%
-58.1%
Q4 2018$23,450,000
+7.1%
714,0720.0%2.77%
+32.2%
Q3 2018$21,901,000
+14.5%
714,0720.0%2.10%
+30.6%
Q2 2018$19,130,000714,0721.61%
Other shareholders
AUTOLUS THERAPEUTICS PLC shareholders Q2 2020
NameSharesValueWeighting ↓
TFG Asset Management GP Ltd 1,300,000$17,160,0002.55%
Alphabet Inc. 699,352$9,231,0000.56%
DAFNA Capital Management LLC 100,000$1,320,0000.45%
JUPITER ASSET MANAGEMENT LTD 705,356$9,311,0000.29%
Artal Group S.A. 500,000$6,600,0000.26%
Cormorant Asset Management, LP 479,988$6,336,0000.25%
MPM BioImpact LLC 39,740$525,0000.19%
Granahan Investment Management 305,158$4,028,0000.18%
Burrage Capital Management LLC 13,113$173,0000.12%
Vident Investment Advisory, LLC 118,866$1,569,0000.10%
View complete list of AUTOLUS THERAPEUTICS PLC shareholders